· Published by Health Canada · Official notice
This is duplicated text of a letter from Hoffmann-La Roche Limited. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
August 20, 2013
Subject: ZELBORAF® (vemurafenib) and the Risk of Progression of Certain Types of Cancer and the Risk of Serious Rash
Hoffmann-La Roche Limited (Roche Canada), in collaboration with Health Canada, would like to inform you of new important safety information with ZELBORAF (vemurafenib) treatment regarding the risk of progression of certain types of cancer and the risk of serious rash.
ZELBORAF is used to treat a type of skin cancer that has a mutation in a gene called the BRAF gene and that cannot be removed by surgery or has spread to other parts of the body.
Risk of Progression of Certain Types of Cancer
Risk of Serious Rash
Roche Canada will be working with Health Canada to update the safety information for ZELBORAF.
Roche Canada has sent a letter to health care professionals informing them of this important safety information. This information may also be obtained on the Roche Canada Web site.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Any case of cancer progression, serious rash or other serious or unexpected adverse reactions in patients receiving ZELBORAF should be reported to Roche or Health Canada.
Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at: 1-888-762-4388
or Fax at: 905-542-5864
or email to: mississauga.drug_safety@roche.com
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of ZELBORAF, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388 from 8:30 a.m. to 4:30 p.m. Monday to Friday Eastern Standard Time.
original signed by
Lorenzo Biondi,
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited